RxDoctor Payments DataLook up a doctor →

Adel Barkat, MD

Vascular Surgery · Tulsa, OKNPI 1467776476

Payments from drug & device makers

$458,567in general payments, 2019–2025

Across 1,330 payments — averaging $344.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$179K
  • Silk Road Medical, Inc.$170K
  • Shockwave Medical, Inc$27K
  • Medtronic$22K
  • Boston Scientific$21K
  • Abiomed$7K
  • plus $33K from 41 others
$6,500in research payments, 2019–2025

Across 1 payment — averaging $6500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$7K

What the payments were for

  • Consulting fees$153,61333%
  • Speaking & faculty fees$148,15032%
  • Travel & lodging$88,49019%
  • Food & beverage$68,31515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$458,567 in reported general payments places this provider in the 95th percentile of 35 vascular surgery providers in Oklahoma.

See all vascular surgery providers in Oklahoma

Medicare billing

Part B allowed, 2024
$243,327
Medicare patients
404
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban67$47,848
EliquisApixaban57$43,968
BrilintaTicagrelor16$11,369
ClopidogrelClopidogrel Bisulfate356$2,521
Atorvastatin Calcium37$516
Ciprofloxacin Hcl23$161
Famotidine21$63
Prednisone22$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$913$47,84867 claims
AstraZenecaBrilinta$18$11,36916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 vascular surgery providers in Oklahoma.

Other vascular surgery in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →